- Home
- LIMN vs AMLX Comparison
LIMN vs AMLX Comparison
Compare LIMN & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LIMN
- AMLX
- Stock Information
- Founded
- LIMN 2018
- AMLX 2014
- Country
- LIMN United States
- AMLX United States
- Employees
- LIMN N/A
- AMLX N/A
- Industry
- LIMN
- AMLX Biotechnology: Pharmaceutical Preparations
- Sector
- LIMN
- AMLX Health Care
- Exchange
- LIMN NYSE
- AMLX Nasdaq
- Market Cap
- LIMN 623.8M
- AMLX 684.6M
- IPO Year
- LIMN N/A
- AMLX 2022
- Fundamental
- Price
- LIMN $5.93
- AMLX $7.72
- Analyst Decision
- LIMN
- AMLX Strong Buy
- Analyst Count
- LIMN 0
- AMLX 7
- Target Price
- LIMN N/A
- AMLX $12.00
- AVG Volume (30 Days)
- LIMN 987.0K
- AMLX 1.5M
- Earning Date
- LIMN 01-01-0001
- AMLX 08-07-2025
- Dividend Yield
- LIMN N/A
- AMLX N/A
- EPS Growth
- LIMN N/A
- AMLX N/A
- EPS
- LIMN N/A
- AMLX N/A
- Revenue
- LIMN N/A
- AMLX N/A
- Revenue This Year
- LIMN N/A
- AMLX N/A
- Revenue Next Year
- LIMN N/A
- AMLX N/A
- P/E Ratio
- LIMN N/A
- AMLX N/A
- Revenue Growth
- LIMN N/A
- AMLX N/A
- 52 Week Low
- LIMN $4.40
- AMLX $1.76
- 52 Week High
- LIMN $33.66
- AMLX $8.72
- Technical
- Relative Strength Index (RSI)
- LIMN N/A
- AMLX 54.70
- Support Level
- LIMN N/A
- AMLX $7.84
- Resistance Level
- LIMN N/A
- AMLX $8.29
- Average True Range (ATR)
- LIMN 0.00
- AMLX 0.45
- MACD
- LIMN 0.00
- AMLX -0.13
- Stochastic Oscillator
- LIMN 0.00
- AMLX 2.90
About LIMN LIMINATUS PHARMA INC
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.